journal
https://read.qxmd.com/read/38241896/altered-lipid-metabolism-in-patients-with-acute-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation
#21
JOURNAL ARTICLE
Martyna Tyszka, Dominika Maciejewska-Markiewicz, Daniel Styburski, Jarosław Biliński, Agnieszka Tomaszewska, Ewa Stachowska, Grzegorz W Basak
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the sole curative option for many hematological malignancies and other diseases. Nevertheless, its application is limited due to the risk of life-threatening complications, mainly graft-versus-host disease (GVHD). Currently, in clinical practice, the risk of developing GVHD is estimated for every patient based on factors related to the donor and the host. In our prospective, observational study, we analyzed serum from 38 patients undergoing allo-HCT at our institution...
January 5, 2024: Leukemia Research
https://read.qxmd.com/read/38460433/efficacy-and-safety-of-mitoxantrone-etoposide-and-cytarabine-for-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia
#22
JOURNAL ARTICLE
Sharon Zhong, Heena Kurish, Robert Walchack, Hong Li, Jessi Edwards, Abhay Singh, Anjali Advani
BACKGROUND/RATIONALE: Most patients with acute myeloid leukemia (AML) develop relapsed or refractory (R/R) disease after receiving initial induction chemotherapy. Salvage chemotherapy followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative therapy for R/R AML. Mitoxantrone, etoposide, and cytarabine (MEC) is the current standard of care salvage regimen for R/R AML at Cleveland Clinic. The primary objective was to determine the overall remission rate (ORR: defined as patients achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi)) in R/R AML patients who received MEC...
April 2024: Leukemia Research
https://read.qxmd.com/read/38335816/systematic-review-and-meta-analysis-evaluating-clinical-outcomes-in-adult-acute-myeloid-leukemia-patients-with-central-nervous-system-involvement
#23
JOURNAL ARTICLE
Hannah Goulart, Dahniel Sastow, Erin Moshier, Lily Martin, John Mascarenhas, Douglas Tremblay
Patients with acute myeloid leukemia (AML) may experience extramedullary involvement when disease is present outside of the blood and bone marrow. In particular, the presence of central nervous system (CNS) involvement has traditionally been thought of as a poor prognostic factor. In the presently available literature, there is a paucity of conclusive data surrounding CNS AML given its rarity and lack of unified screening practices. Thus, we performed a systematic review and meta-analysis in order to more definitively characterize survival outcomes in this patient population...
February 2024: Leukemia Research
https://read.qxmd.com/read/38301422/myelodysplastic-neoplasms-evolving-from-inherited-bone-marrow-failure-syndromes-germline-predisposition-syndromes-back-under-the-microscope
#24
REVIEW
M Tarek Elghetany, Mrinal M Patnaik, Joseph D Khoury
Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or more cell lines...
February 2024: Leukemia Research
https://read.qxmd.com/read/38278044/phase-2-trial-of-induction-with-dasatinib-and-consolidation-with-hyper-cvad-plus-dasatinib-followed-by-allografting-for-ph-positive-acute-lymphoblastic-leukemia-in-adults
#25
LETTER
Iekuni Oh, Kaoru Hatano, Takashi Ikeda, Yumiko Toda, Daisuke Minakata, Shinichiro Kawaguchi, Kaoru Morita, Chihiro Yamamoto, Masahiro Ashizawa, Kazuya Sato, Kazuaki Kameda, Ayumi Gomyo, Yukiko Misaki, Shunto Kawamura, Shunichi Kimura, Hiroyuki Kobayashi, Hiroyuki Sato, Hideki Nakasone, Ken Ohmine, Shinichiro Fujiwara, Shinichi Kako, Yoshinobu Kanda
No abstract text is available yet for this article.
February 2024: Leukemia Research
https://read.qxmd.com/read/38154193/the-clinical-molecular-and-prognostic-features-of-the-2022-who-and-icc-classification-systems-for-myelodysplastic-neoplasms
#26
JOURNAL ARTICLE
Vishesh Khanna, Rong Lu, Jyoti Kumar, Alfonso Molina, Henning Stehr, Elizabeth Spiteri, Michael Spinner, Oscar Silva, Sebastian Fernandez-Pol, Brent Tan, Peter L Greenberg
Myelodysplastic neoplasms (MDS) are clonal disorders of bone marrow failure exhibiting a variable risk of progression to acute myeloid leukemia. MDS exhibit certain prognostic genetic or cytogenetic abnormalities, an observation that has led to both the pathologic reclassification of MDS in the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) systems, as well as to an updated prognostic schema, the Molecular International Prognostic Scoring System (IPSS-M). This single-institution study characterized the molecular patterns and clinical outcomes associated with the 2022 WHO and ICC classification schemas to assess their clinical utility...
January 2024: Leukemia Research
https://read.qxmd.com/read/38154192/spectrum-of-therapy-related-clonal-cytopenias-and-neoplasms-after-exposure-to-lutetium-177-dotatate
#27
LETTER
Stephanie L Pritzl, Yael Kusne, Thorvardur R Halfdanarson, Timothy Hobday, Mohamad Bassam Sonbol, Ayse Tuba Kendi, Abhishek A Mangaonkar, Naseema Gangat, Mithun Shah, Mrinal M Patnaik
No abstract text is available yet for this article.
December 25, 2023: Leukemia Research
https://read.qxmd.com/read/38159331/vexas-syndrome-in-a-patient-with-ddx41-germline-predisposition-syndrome
#28
LETTER
Yael Kusne, Terra Lasho, Christy Finke, Mrinal M Patnaik, Talha Badar
No abstract text is available yet for this article.
December 15, 2023: Leukemia Research
https://read.qxmd.com/read/37956474/how-low-can-you-go-methodologic-considerations-in-clonal-hematopoiesis-variant-calling
#29
REVIEW
J Scott Beeler, Kelly L Bolton
Clonal hematopoiesis (CH) is defined by the presence of an expanded clonal hematopoietic cell population due to an acquired mutation conferring a selective growth advantage and is known to predispose to hematologic malignancy. In this review, we discuss sequencing methods for CH detection in bulk sequencing data and corresponding bioinformatic approaches for variant calling, filtering, and curation. We detail practical recommendations for CH calling. Finally, we discuss how improvements in CH sequencing and bioinformatic approaches will enable the characterization of CH trajectories, its impact on human health, and therapeutic approaches to mitigate its adverse effects...
December 2023: Leukemia Research
https://read.qxmd.com/read/37944240/advances-in-diagnosis-treatment-and-prognostic-factors-of-gastrointestinal-dlbcl
#30
REVIEW
Qinqiao Lai, Yan Zhao, Haiqing Yan, Hongling Peng
Gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) is an extremely aggressive form of B-cell non-Hodgkin lymphoma (BNHL) which has complex histological characteristics and manifests a high degree of heterogeneity in terms of clinical, morphological, immunological, and genetic features. GI-DLBCL mainly spreads by infiltrating neighboring lymph nodes, and common gastrointestinal complications (GICS) such as obstruction, perforation, or bleeding, frequently arise during the progression of the disease, posing significant challenges in both diagnosing and treating the condition...
December 2023: Leukemia Research
https://read.qxmd.com/read/37918224/a-comprehensive-comparison-between-tbi-vs-non-tbi-based-conditioning-regimen-in-pediatric-patients-with-acute-lymphoblastic-leukemia-a-systematic-review-and-meta-analysis
#31
REVIEW
Faezeh Ansari, Maryam Behfar, Leila Jafari, Rashin Mohseni, Parisa Naji, Yalda Karamlou, Mohammad Hossein Amirzade-Iranaq, Amir Ali Hamidieh
INTRODUCTION: We aimed to evaluate the efficacy, safety, and latent toxicity of total body irradiation (TBI)-based conditioning regimens compared to non-TBI regimens for pediatric patients (under 18 years old) with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: A systematic search was performed on MEDLINE, Scopus, WOS, and PMC. Also, a search for grey literature was performed on Google Scholar and relevant articles' references were included...
December 2023: Leukemia Research
https://read.qxmd.com/read/38043326/evaluation-of-palonosetron-fosaprepitant-and-olanzapine-as-antiemetic-prophylaxis-for-fludarabine-and-melphalan-based-conditioning-regimens-prior-to-allogeneic-hematopoietic-stem-cell-transplants
#32
JOURNAL ARTICLE
Riley Karpen, Jeremy Sen, Sarah Wall, Samantha Musson, Justin Tossey
BACKGROUND: Limited data are available regarding efficacious antiemetic regimens to prevent chemotherapy-induced nausea and vomiting (CINV) for patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). In patients aged 60 years or older, allogeneic HSCT is associated with improved survival, but tolerability of the transplant is a significant barrier. Fludarabine and melphalan (Flu-Mel) is a frequently utilized multi-day reduced intensity conditioning regimen for allogeneic HSCT...
November 28, 2023: Leukemia Research
https://read.qxmd.com/read/38008060/low-intensity-venetoclax-based-salvage-as-a-bridge-to-allogeneic-stem-cell-transplant-in-patients-with-acute-myeloid-leukemia-failing-conventional-intensive-chemotherapy
#33
LETTER
Michael Ashby, Shaun Fleming, Tse-Chieh Teh, Ing Soo Tiong, Shafqat Inam, David J Curtis, Sushrut Patil, Catherine Vassili, Chong Chyn Chua
No abstract text is available yet for this article.
November 23, 2023: Leukemia Research
https://read.qxmd.com/read/38042648/sorafenib-in-combination-with-intensive-chemotherapy-for-relapsed-or-refractory-flt3-itd-positive-acute-myeloid-leukemia-a-two-centers-experience
#34
LETTER
Irene Urbino, Carolina Secreto, Vincenzo Apolito, Matteo Olivi, Giulia Arrigo, Eleonora Boscaro, Federica Maria Catania, Stefano D'Ardia, Chiara Frairia, Valentina Giai, Roberto Freilone, Benedetto Bruno, Giuseppe Lanzarone, Luisa Giaccone, Alessandro Busca, Chiara Maria Dellacasa, Dario Ferrero, Ernesta Audisio, Marco Cerrano
No abstract text is available yet for this article.
November 18, 2023: Leukemia Research
https://read.qxmd.com/read/38016412/the-molecular-landscape-of-myeloproliferative-neoplasms-associated-with-splanchnic-vein-thrombosis-current-perspective
#35
REVIEW
Carlo Pescia, Gianluca Lopez, Daniele Cattaneo, Cristina Bucelli, Umberto Gianelli, Alessandra Iurlo
BCR::ABL1-negative myeloproliferative neoplasms (MPNs) are classically represented by polycythemia vera, essential thrombocythemia, and primary myelofibrosis. BCR::ABL1-negative MPNs are significantly associated with morbidity and mortality related to an increased risk of thrombo-hemorrhagic events. They show a consistent association with splanchnic vein thrombosis (SVT), either represented by the portal, mesenteric or splenic vein thrombosis, or Budd-Chiari Syndrome. SVT is also a frequent presenting manifestation of MPN...
November 10, 2023: Leukemia Research
https://read.qxmd.com/read/37729719/harnessing-autologous-immune-effector-mechanisms-in-acute-myeloid-leukemia-2023-update-of-trials-and-tribulations
#36
REVIEW
Shyam A Patel, Elisa Bello, Andrew Wilks, Jonathan M Gerber, Narayanan Sadagopan, Jan Cerny
Numerous recent advances have been made in therapeutic approaches toward acute myeloid leukemia (AML). Since 2017, we have seen eleven novel Food & Drug Administration (FDA)-approved medications for AML, all of which extend beyond the classical cytarabine-based cytostatic chemotherapy. In the recent two decades, the role of immune surveillance in AML has been intensively investigated. The power of one's own innate and adaptive immunity has been harnessed pharmacologically toward the goal of clearance of AML cells...
November 2023: Leukemia Research
https://read.qxmd.com/read/37672954/the-shifting-therapeutic-paradigm-for-relapsed-refractory-mantle-cell-lymphoma
#37
REVIEW
Sumukh Arun Kumar, Jenny Gao, Shyam A Patel
Mantle cell lymphoma (MCL) is a heterogeneous subtype of non-Hodgkin lymphoma that has been historically associated with poor 5-year overall survival rates, especially for aggressive variants. Traditional cytotoxic chemotherapy had been a mainstay of therapy for relapsed/refractory (R/R) MCL for many years until the advent of molecularly targeted therapies and cell-based approaches. However, a significant concern is the lack of definitive consensus guidelines for management of R/R MCL. The managerial conundrum partly stems from the absence of head-to-head comparisons of novel therapies, with conclusions drawn from cross-trial comparisons...
November 2023: Leukemia Research
https://read.qxmd.com/read/37925761/venetoclax-based-therapy-in-treatment-na%C3%A3-ve-and-relapsed-refractory-acute-myeloid-leukemia
#38
LETTER
Aditya Ravindra, Luna Acharya, Bradley Loeffler, Sarah Mott, Grerk Sutamtewagul, Prajwal Dhakal
Combining venetoclax with the hypomethylating agents azacitidine or decitabine has shown high complete response rates (60-70 %) in newly diagnosed (ND) acute myeloid leukemia (AML). However, studies addressing the efficacy of this approach in relapsed/refractory (R/R) AML remain limited. We conducted a retrospective analysis on patients treated with venetoclax-based therapy at a single institution. Objective response rates (ORR) and overall survival (OS) were assessed using logistic regression and Cox regression models, respectively...
October 31, 2023: Leukemia Research
https://read.qxmd.com/read/37953091/prmt5-inhibitors-for-lower-risk-myelodysplasia-is-there-anywhere-to-move
#39
EDITORIAL
Andrej Terzic, David J Curtis
No abstract text is available yet for this article.
October 26, 2023: Leukemia Research
https://read.qxmd.com/read/37864958/a-new-sequential-conditioning-regimen-based-on-cpx-351-vyxeos-vyx-seq-in-patients-with-higher-risk-myelodysplastic-syndromes
#40
LETTER
A B Notarantonio, G Roth-Guépin, C Bonmati, M Divoux, C Kicki, S Pagliuca, A Campidelli, M T Rubio, M D'Aveni-Piney
No abstract text is available yet for this article.
October 16, 2023: Leukemia Research
journal
journal
27133
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.